Savolitinib
CAS 1313725-88-0 2 FDA-DMF suppliersSmall Molecule
Overview
Savolitinib is a potent, selective small molecule inhibitor of the c-Met receptor tyrosine kinase. It is being investigated for its potential in treating various types of cancer, especially non-small cell lung cancer.
Therapeutic areas
OncologyLung Cancer
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.